CSL's biosciences sales rise 19% in fiscal 1994
This article was originally published in Clinica
Executive Summary
The Biosciences division of CSL (Australia) saw its turnover rise 19% to Au$16.9 million ($13 million) in fiscal 1994 (ended June). CSL says it holds the major market share in Australian blood bank diagnostics and cell culture reagent businesses. The company has developed a diagnostic screening test for TB based on cell-mediated immunity (CMI) technology. "Interim results from clinical trials suggest this new test is superior to existing screening methods," CSL notes in its annual report.